Pregnancy, Childbirth & Puerperium

Vasa previa and velamentous cord insertion

Clinical Overview and When to Suspect Vasa Previa

— Type I: associated with velamentous cord insertion (cord inserts into membranes rather than placental disk, so vessels run unsupported through chorioamniotic membranes before reaching placenta)

— Type II: vessels connect lobes of a bilobed or succenturiate-lobe placenta, crossing over the os

— Routine second-trimester anatomy scan flags low-lying placenta, bilobed/succenturiate placenta, placenta previa that resolves, IVF pregnancy, or multiple gestation

— Painless vaginal bleeding immediately after rupture of membranes accompanied by fetal bradycardia or sinusoidal heart tracing

— Palpation of pulsating vessels through dilated cervix during labor exam

Definition: Vasa previa = unprotected fetal vessels traverse the membranes overlying or within 2 cm of the internal cervical os, ahead of the presenting part

Velamentous cord insertion (VCI): umbilical vessels insert into the membranes ~1–10 cm from the placental edge; ~1% of singletons, ~15% of monochorionic twins — a precursor lesion to vasa previa but not synonymous

Why it matters: When membranes rupture (spontaneous or artificial), exposed fetal vessels can tear → rapid fetal exsanguination; perinatal mortality approaches 60% if undiagnosed antenatally, but exceeds 97% survival when diagnosed prenatally and delivered by scheduled cesarean

When to suspect on Step 3:

Risk factors: IVF/ART (3–6× risk), multiple gestation, second-trimester low-lying placenta or placenta previa, bilobed/succenturiate placenta, velamentous cord insertion

Board pearl: Vasa previa is the classic triad of rupture of membranes → painless vaginal bleeding → fetal distress (sinusoidal or bradycardic tracing). Bleeding is fetal blood, so even small volumes (50–100 mL) cause catastrophic fetal compromise because fetal blood volume is only ~80–100 mL/kg

Presentation Patterns and Key History

— Detected on transabdominal anatomy ultrasound (18–22 weeks) showing velamentous cord insertion, succenturiate or bilobed placenta, or low-lying placenta

— Confirmation with transvaginal ultrasound + color Doppler demonstrating vessels crossing/within 2 cm of internal os

— History clues: IVF conception, twin pregnancy, prior placenta previa, second-trimester placenta previa that "migrated" upward

— Sudden painless vaginal bleeding immediately after spontaneous or artificial rupture of membranes

— Accompanied by acute fetal heart rate abnormalities: sinusoidal pattern (classic for fetal anemia), prolonged bradycardia, or recurrent variable/late decelerations

— Maternal vitals typically normal because blood loss is fetal, not maternal — a critical distinguishing feature

— Pulsating vessels palpable through dilated cervix or visible on speculum

— Membranes may show vessels traversing them (rarely visualized directly)

— Mode of conception (IVF)?

— Prior ultrasound reports mentioning placental morphology or cord insertion site?

— Bleeding timing relative to ROM (vasa previa bleeds with ROM; placenta previa bleeds without trigger; abruption bleeds with pain and uterine tonicity)

Antenatal (asymptomatic) discovery — the goal:

Intrapartum (catastrophic) presentation:

Labor exam findings:

History pearls to ask:

Velamentous cord insertion specifically: often asymptomatic; may present as fetal growth restriction, abnormal fetal heart tracing in labor, or retained placenta; in monochorionic twins it raises risk of TTTS and selective IUGR

Key distinction: In placenta previa, maternal hemodynamics deteriorate with bleeding; in vasa previa, the mother is stable but the fetus crashes — this single feature drives the management urgency and counseling

Physical Exam Findings (and Hemodynamic Assessment)

— Typically normal — BP, HR, perfusion preserved because hemorrhage is fetal

— If maternal instability is present, reconsider diagnosis (placental abruption, uterine rupture, or placenta previa more likely)

— Soft, non-tender uterus (distinguishes from abruption which is rigid/tender)

— No uterine hypertonus

— Leopold maneuvers: variable presentation; fetal lie may be normal

— Blood at cervical os, often dark or bright red

— Rarely, pulsating vessels visible through dilated cervix

— Apt test (alkali denaturation) or Kleihauer-Betke on shed blood can confirm fetal origin (fetal hemoglobin resists alkali denaturation, remains pink; adult Hb turns yellow-brown) — historically used but rarely practical in acute setting

— Continuous external fetal monitoring

— Sinusoidal pattern: smooth, undulating wave-like baseline with 5–15 bpm amplitude, 3–5 cycles/min — pathognomonic for fetal anemia/hypoxia

— Prolonged bradycardia (<110 bpm >10 min), recurrent late decelerations, loss of variability

— Category III tracing mandates immediate delivery

— Avoid if vasa previa suspected — can rupture vessels

— If pulsating cord-like structure felt at os, stop, do not displace, and proceed to emergent cesarean

Maternal vital signs:

Abdominal exam:

Speculum exam (perform carefully if vasa previa suspected, avoid digital exam):

Fetal hemodynamic assessment — the priority:

Digital cervical exam:

CCS pearl: When you suspect vasa previa intrapartum, your first orders should be: continuous fetal monitoring, large-bore IV access, type and crossmatch, mobilize OR for stat cesarean, notify neonatology for neonatal resuscitation including possible transfusion — do NOT order a digital cervical exam, and do NOT delay for confirmatory imaging

Diagnostic Workup — Initial Imaging and Screening

— Routine second-trimester anatomy scan (18–22 weeks) should evaluate placental cord insertion site and placental morphology (bilobed, succenturiate lobe, low-lying)

— Identification of velamentous insertion or accessory lobe triggers targeted vasa previa evaluation

— Gold standard for vasa previa diagnosis

— Demonstrates linear echolucent structures over the internal os with pulsatile Doppler flow at fetal heart rate (distinguishes from maternal uterine vessels which show maternal HR)

— Performed at 28–32 weeks for suspected cases, with repeat scan at 32 weeks to confirm persistence (some "vasa previa" resolve as lower segment develops)

— Velamentous cord insertion identified on routine scan

— Bilobed or succenturiate-lobe placenta

— Second-trimester low-lying placenta or placenta previa

— IVF pregnancies

— Multiple gestation (especially monochorionic)

— Some societies (SMFM) endorse targeted screening; universal cord insertion documentation is increasingly standard

— Maternal CBC, type and crossmatch, coagulation panel — typically normal early

— Apt test on vaginal blood — fetal Hb pink; rarely used acutely

— Kleihauer-Betke quantifies fetomaternal hemorrhage but does not change acute management

Transabdominal ultrasound (TAUS) — screening modality:

Transvaginal ultrasound (TVUS) with color Doppler — confirmatory:

Who to screen specifically:

Labs (if intrapartum bleeding):

Fetal heart rate monitoring: continuous external monitoring is the single most actionable diagnostic in suspected acute vasa previa

Step 3 management: If second-trimester ultrasound flags velamentous cord insertion or accessory placental lobe, order TVUS with color Doppler at 28–32 weeks to evaluate for vasa previa — do not wait for symptoms. Documenting cord insertion is now considered standard of care on the anatomy scan

Diagnostic Workup — Advanced and Confirmatory Studies

— Pulsed Doppler over the suspected vessel reveals fetal-rate waveform (typically 110–160 bpm) vs maternal uterine vessels (60–90 bpm)

— Vessels lie within the membranes overlying the os, not within placental tissue

— Three-dimensional ultrasound and power Doppler can map vessel course but are adjunctive

— Reserved for equivocal cases or when ultrasound is technically limited (maternal habitus, posterior placenta)

— Demonstrates vessels traversing the lower uterine segment

— Not routine; ultrasound is the workhorse

— Marginal cord insertion: cord inserts <2 cm from placental edge but still on disk — lower risk than velamentous, generally no vasa previa workup needed unless other risk factors

— Funic presentation: umbilical cord (not unprotected vessels) lies between presenting part and cervix — transient, may resolve; managed differently

— Low-lying placenta with marginal sinus: maternal vessels; Doppler shows maternal heart rate

— Initial detection in second trimester → repeat TVUS at 32 weeks to confirm persistence

— ~15–20% of suspected vasa previa resolve as the lower segment elongates

— Persistent vasa previa at 32 weeks → plan delivery at 34 0/7–37 0/7 weeks per SMFM

— Once diagnosed and managed expectantly, weekly nonstress tests starting at 28–32 weeks

— Consider antenatal corticosteroids for fetal lung maturity given planned late-preterm delivery (betamethasone at 28–32 weeks if hospitalized, or with first dose closer to delivery)

Transvaginal color and pulsed-wave Doppler — definitive:

MRI:

Differentiating mimics on imaging:

Repeat scanning timing:

Antenatal fetal surveillance:

Board pearl: The single discriminating Doppler finding is fetal heart rate in the vessel waveform. A pulsatile vessel over the os with fetal HR = vasa previa; same location with maternal HR = uterine vessel, not vasa previa. This question shows up verbatim on exams

Risk Stratification and Management Logic

— Goal: avoid spontaneous labor and ROM

— Hospitalization at 30–34 weeks for continuous monitoring (controversial; some manage outpatient with strict precautions if reliable, close to hospital)

— Antenatal corticosteroids (betamethasone) at 28–32 weeks for fetal lung maturity

— Scheduled cesarean delivery at 34 0/7 to 37 0/7 weeks before labor onset — SMFM recommends 34 0/7–35 6/7 if symptomatic or high-risk, 35–37 weeks for stable asymptomatic cases

— Pelvic rest, avoid intercourse, no digital cervical exams

— Increased risk of FGR, low birth weight, abnormal FHR in labor, retained placenta

— Serial growth ultrasounds (every 3–4 weeks from 28 weeks)

— Vaginal delivery is acceptable if no vasa previa; continuous intrapartum fetal monitoring

— No indication for early or cesarean delivery solely for VCI

— Emergent cesarean delivery — every minute matters

— Prepare for neonatal resuscitation with volume expansion and transfusion (O-negative uncrossmatched blood)

— Monochorionic twins with VCI: increased TTTS, sIUGR risk; serial Doppler surveillance

— Plan delivery timing per chorionicity guidelines, modified for vasa previa

Antenatally diagnosed vasa previa — the favorable scenario:

Velamentous cord insertion without vasa previa:

Acute intrapartum vasa previa (undiagnosed, bleeding + fetal distress):

Multiple gestation considerations:

Step 3 management: For antenatally diagnosed vasa previa, the management algorithm is: (1) confirm at 32 weeks TVUS, (2) corticosteroids 28–32 weeks, (3) hospitalization 30–34 weeks for monitoring, (4) scheduled cesarean at 34 0/7–37 0/7 weeks before labor. Vaginal delivery is absolutely contraindicated — this is one of the few obstetric scenarios with a hard cesarean indication

Pharmacotherapy and Antenatal Optimization

— Betamethasone 12 mg IM q24h × 2 doses (or dexamethasone 6 mg IM q12h × 4 doses) administered at 28–32 weeks given anticipated late-preterm delivery

— Reduces neonatal RDS, IVH, necrotizing enterocolitis, and mortality

— A second "rescue" course may be considered if delivery occurs >14 days after initial course and before 34 weeks

— Late-preterm steroids (34 0/7–36 6/7 weeks) reduce respiratory morbidity if delivery anticipated within 7 days and no prior course given

— Indicated if delivery anticipated <32 weeks for neonatal neuroprotection (reduces cerebral palsy risk)

— Loading 4–6 g IV over 20–30 min, then 1–2 g/hr infusion

— Not typically needed if planned delivery at 34–37 weeks

— May be used briefly (24–48 h) to permit corticosteroid course completion if preterm labor develops before scheduled delivery

— Agents: nifedipine, indomethacin (<32 weeks), terbutaline

— Not indicated if bleeding active or fetal status non-reassuring → proceed to delivery

— Standard 300 µg IM at 28 weeks for Rh-negative mothers

— Additional dose postpartum if neonate Rh-positive

— Kleihauer-Betke after bleeding event to quantify need for additional RhIg

— Type and screen on admission; type and crossmatch 2 units PRBCs available before scheduled cesarean

— Neonatology should have O-negative uncrossmatched blood available in OR

Antenatal corticosteroids — cornerstone:

Magnesium sulfate for neuroprotection:

Tocolysis:

Rh immunoglobulin:

Anti-D and crossmatch readiness:

Board pearl: No pharmacotherapy "treats" vasa previa — the only definitive therapy is delivery before membrane rupture. Drug management focuses on fetal lung maturity (steroids), neuroprotection (Mg if <32 weeks), and Rh prophylaxis. Don't confuse this with abruption or previa management

Procedural Management — Cesarean Delivery Planning

— Timing: 34 0/7 to 37 0/7 weeks depending on stability, comorbidities, and prior bleeding

— SMFM 2015: deliver 34 0/7–35 6/7 weeks for typical vasa previa; some experts extend to 36–37 weeks for stable, asymptomatic, no prior bleeding

— Performed before labor onset and before ROM

— Type and crossmatch 2 units maternal PRBCs

— O-negative uncrossmatched blood available for neonate (target 10–20 mL/kg if anemic)

— Neonatology and NICU team at delivery

— Anesthesia: regional preferred unless emergent or contraindicated

— Confirm fetal vessel location with bedside ultrasound in OR before incision

— Standard low transverse uterine incision when possible

— Map the vessels intraoperatively with ultrasound and avoid transecting them during hysterotomy

— Consider classical (vertical) incision if vessels traverse the lower segment in a way that low-transverse would lacerate them

— Clamp cord promptly after delivery to limit neonatal blood loss

— Decision-to-delivery interval <20 minutes ideal

— General anesthesia often required for speed

— Neonatal team must be prepared for immediate volume resuscitation and transfusion — neonate may arrive in hemorrhagic shock

— Cord blood sampling for Hgb/Hct

— If anemic/shocked: O-negative PRBC 10–20 mL/kg, consider whole blood, correct acidosis

— NICU admission likely

Scheduled cesarean — the definitive intervention:

Preoperative preparation:

Surgical technique:

Emergent cesarean for acute vasa previa rupture:

Neonatal management at delivery:

CCS pearl: For acute intrapartum vasa previa, your CCS orders should flow: call OR stat, mobilize anesthesia and neonatology, place 2 large-bore IVs, type and crossmatch, transfer to OR, general anesthesia, stat cesarean, neonatal resuscitation with O-neg blood available. Do not order tocolytics, do not attempt vaginal delivery, do not delay for additional imaging

Special Populations — Maternal Comorbidities

— Increased baseline risk of placental anomalies including velamentous insertion and accessory lobes

— Higher rate of IVF conception — additional vasa previa risk

— No modification of delivery timing based solely on age

— Anesthesia consultation early

— For cardiac patients, plan cesarean in setting with appropriate monitoring (telemetry, possibly cardiac OR)

— Volume management critical — these patients tolerate hemorrhage poorly

— Correct coagulation defects preoperatively (FFP, platelets, vitamin K as needed)

— Cholestasis of pregnancy or HELLP modify timing — may necessitate earlier delivery

— Optimize iron stores antenatally; IV iron if oral inadequate

— For Jehovah's Witness, document blood product preferences in advance directive

— Cell saver may be acceptable to some patients; coordinate with hematology

— Higher cesarean morbidity, wound complications, VTE risk

— Preoperative chlorhexidine, vaginal prep, mechanical and pharmacologic VTE prophylaxis

— Imaging more challenging — may need MRI confirmation of vasa previa

— Glycemic control reduces neonatal complications including hypoglycemia and macrosomia

— Late-preterm delivery for vasa previa may compound neonatal risks — coordinate with endocrinology and neonatology

— Pregnancy + cesarean + immobility = high risk

— Sequential compression devices intraoperatively; pharmacologic prophylaxis postpartum per ACOG guidance

Advanced maternal age (≥35):

Maternal cardiovascular or renal disease:

Hepatic impairment / coagulopathy:

Maternal anemia / Jehovah's Witness:

Obesity:

Diabetes (pregestational or gestational):

VTE risk:

Key distinction: Maternal comorbidities rarely change the diagnosis of vasa previa but heavily influence delivery timing, anesthesia plan, and postpartum management. Coordinate with MFM, anesthesia, and relevant subspecialists early — ideally a multidisciplinary plan by 28–30 weeks

Special Populations — Multiple Gestation and IVF

— 3–6× increased risk of vasa previa and velamentous insertion

— Mechanism: abnormal early implantation, increased frequency of placental anomalies

— Universal screening for cord insertion at anatomy scan recommended in IVF pregnancies

— Vasa previa more common, especially in monochorionic twins (shared placenta, more anomalous insertions)

— Velamentous insertion in ~15% of MC twins vs ~1% of singletons

— Increased TTTS, sIUGR risk independent of vasa previa

— Delivery timing for twins with vasa previa typically 34–35 weeks (earlier than singletons due to twin baseline morbidity)

— Already plan delivery 36–37 weeks

— With vasa previa, deliver 34–35 weeks

— Serial growth and Doppler surveillance for TTTS

— Standard delivery 38 weeks

— With vasa previa, deliver 34–37 weeks

— Late-preterm neonates (34–37 weeks) at risk for transient tachypnea, hypoglycemia, hyperbilirubinemia, feeding difficulty, temperature instability

— Antenatal corticosteroids reduce RDS even at 34–36 weeks

— Neonatal anemia from acute vasa previa rupture requires immediate transfusion, monitoring for HIE

— Long-term: most neonates with antenatally diagnosed vasa previa have normal neurodevelopmental outcomes if delivered before rupture

In vitro fertilization (IVF) / ART:

Multiple gestation:

Monochorionic-diamniotic (MCDA) twins:

Dichorionic-diamniotic (DCDA) twins:

Pediatric/neonatal considerations:

Step 3 management: Every IVF pregnancy and every twin pregnancy warrants explicit documentation of cord insertion site and placental morphology at the 18–22 week anatomy scan. If velamentous insertion or accessory lobe is identified, follow up with TVUS color Doppler at 28–32 weeks to rule out vasa previa — this is a high-yield USMLE management decision point

Complications and Adverse Outcomes

— Fetal exsanguination and death — mortality 56–60% when undiagnosed antenatally vs <3% when diagnosed and managed

— Hypovolemic shock, anemia, hypoxic-ischemic encephalopathy (HIE)

— Neonatal transfusion requirement — up to 60% of acute vasa previa survivors

— Long-term neurodevelopmental impairment from HIE if delivery delayed

— Generally few direct maternal complications because hemorrhage is fetal

— Cesarean-related: bleeding, infection, VTE, anesthesia complications, surgical injury to bladder/bowel

— Emergency cesarean carries higher complication rate than scheduled

— Psychological morbidity: anxiety, PTSD after acute event or pregnancy loss

— Fetal growth restriction (10–15% risk)

— Preterm delivery

— Low Apgar scores, abnormal FHR tracings in labor

— Retained placenta and postpartum hemorrhage (cord avulsion during traction)

— Cord compression in labor → variable decelerations

— Late-preterm delivery morbidity (RDS, TTN, hypoglycemia, feeding difficulty, hyperbilirubinemia) — cost of preventing catastrophe

— Prolonged hospitalization → maternal VTE, deconditioning, psychological strain

— Catastrophic fetal demise during otherwise routine labor

— Major source of obstetric malpractice litigation — failure to identify placental cord insertion or vasa previa on second-trimester ultrasound

Fetal complications (the dominant concern):

Maternal complications:

Velamentous cord insertion–specific complications:

Iatrogenic complications:

Missed diagnosis consequences:

Board pearl: The mortality differential — >50% if undiagnosed vs <3% if diagnosed prenatally — is the single most quoted statistic on board exams. It drives the rationale for universal cord insertion documentation at the anatomy scan and targeted screening of high-risk pregnancies

When to Escalate — Hospitalization, Consults, and Emergencies

— Acute vaginal bleeding after ROM with sinusoidal or bradycardic fetal heart tracing

— Pulsating vessels palpated or visualized at the cervix

— Category III tracing in a patient with known or suspected vasa previa

— Confirmed vasa previa: admit at 30–34 weeks for continuous fetal surveillance, immediate cesarean access

— Some centers use outpatient management with strict criteria: lives close to hospital, reliable, no preterm contractions, weekly NSTs, daily kick counts

— Earlier admission if: prior bleeding episode, short cervix (<25 mm), preterm contractions, multiple gestation

— At time of diagnosis (typically second trimester)

— Coordinates ultrasound surveillance, delivery planning, multidisciplinary management

— Antenatal counseling regarding late-preterm neonatal course

— Present at delivery with resuscitation equipment, O-negative blood

— At 28–32 weeks for delivery planning

— Identifies airway, neuraxial, and hemodynamic concerns in advance

— Type and screen on admission, crossmatch 2 units before scheduled cesarean

— O-negative for neonate available in OR

— If diagnosed at a center without 24/7 cesarean, MFM, neonatology, and blood bank capability — transfer antenatally, not in labor

Immediate emergent escalation (call OR now):

Hospitalization for antenatal monitoring:

Maternal-fetal medicine (MFM) consultation:

Neonatology consultation:

Anesthesia consultation:

Blood bank notification:

Transfer to tertiary center:

CCS pearl: Once vasa previa is confirmed at 32 weeks, your standing orders should include: MFM consult, neonatology consult, anesthesia consult, betamethasone at 28–32 weeks, hospitalize 30–34 weeks, weekly NSTs, type and screen, scheduled cesarean 34–37 weeks, no digital cervical exams. This bundled approach is testable as a sequence

Key Differentials — Other Causes of Antepartum/Intrapartum Bleeding

— Placenta covers or near (within 2 cm) the internal os

— Painless vaginal bleeding, maternal hemodynamic compromise possible

— Diagnosed by TVUS showing placental tissue (not just vessels) over os

— Management: pelvic rest, scheduled cesarean 36 0/7–37 6/7 weeks

— Premature separation of placenta from uterine wall

— Painful vaginal bleeding, rigid/tender uterus, uterine hyperstimulation, maternal hemodynamic instability, fetal distress

— Risk factors: hypertension, cocaine, trauma, PPROM

— Management: stabilize, deliver if fetal/maternal compromise; consider DIC workup

— Catastrophic, often in setting of prior cesarean or uterine surgery

— Sudden severe abdominal pain, loss of station, fetal bradycardia, maternal shock

— Requires emergent laparotomy

— Small amount of blood-tinged mucus with labor onset

— Benign, no fetal distress

— Recent intercourse, instrumentation, speculum exam

— Hemodynamics stable, no fetal distress

— Postcoital bleeding, abnormal Pap or speculum findings

— Rupture of marginal placental venous lake

— Self-limited, usually benign

— First/second-trimester finding; usually resolves

Placenta previa:

Placental abruption:

Uterine rupture:

Bloody show / cervical change:

Cervical or vaginal trauma/laceration:

Cervical lesions (polyp, cancer, cervicitis):

Marginal sinus bleeding:

Subchorionic hematoma:

Key distinction: The combination of painless bleeding + ROM trigger + fetal bradycardia/sinusoidal pattern + stable mother is highly specific for vasa previa. Painful bleeding + tender uterus + maternal instability = abruption. Painless bleeding without ROM trigger + possible maternal instability = placenta previa. Get these three patterns cold for the exam

Key Differentials — Other Categories and Non-Obstetric Mimics

— Hemorrhoidal bleeding — common in pregnancy; perianal exam clarifies

— Urinary tract bleeding — hematuria from UTI, stones; urinalysis

— GI bleeding — peptic disease, hemorrhoids, IBD; melena or hematochezia

— Fetomaternal hemorrhage (FMH): chronic or acute transfer of fetal blood into maternal circulation; presents as decreased fetal movement, sinusoidal tracing, fetal anemia but without vaginal bleeding; diagnosed by Kleihauer-Betke or flow cytometry

— Twin-twin transfusion syndrome (TTTS): monochorionic twins with shared circulation; one anemic, one polycythemic; serial Doppler surveillance detects

— Von Willebrand disease, ITP, hemophilia carriers may present with abnormal bleeding patterns

— Coagulation studies and platelet counts differentiate

— Mild bleeding with contractions and cervical change

— Tocolytics, steroids, magnesium per gestational age

— Painless cervical dilation, may have spotting; second-trimester loss risk

— Diagnosed by cervical length; managed with cerclage if appropriate

— Cervicitis with friable cervix → contact bleeding

— NAAT for gonorrhea/chlamydia, wet mount, treat per guidelines

— Domestic violence, MVC — abdominal trauma can cause abruption or direct fetal injury

— Screen all pregnant patients for intimate partner violence

Maternal bleeding from non-uterine sources:

Fetal bleeding sources other than vasa previa:

Coagulopathies:

Preterm labor with bloody show:

Cervical insufficiency:

Sexually transmitted infections:

Trauma:

Board pearl: When the question stem features "sinusoidal fetal heart tracing without vaginal bleeding", think fetomaternal hemorrhage, not vasa previa. When sinusoidal pattern occurs with bleeding after ROM, think vasa previa. The presence or absence of vaginal bleeding is the discriminator

Secondary Prevention, Discharge Planning, and Long-Term Care

— Standard cesarean recovery: pain control, early ambulation, VTE prophylaxis (mechanical + pharmacologic if obese or other risks)

— Rh immunoglobulin if Rh-negative mother and Rh-positive neonate

— Postpartum hemorrhage risk — slightly increased due to uterine manipulation

— Iron repletion if anemic

— If acute exsanguination event: NICU admission, transfusion (PRBC 10–20 mL/kg), monitor for HIE, therapeutic hypothermia if moderate-to-severe HIE per neonatal criteria

— Late-preterm: monitor glucose, temperature, feeding, bilirubin

— Hearing screen, follow neurodevelopment

— Recurrence risk for vasa previa is low (no strong familial pattern) but recurrence of placental anomalies (accessory lobe, velamentous insertion) is increased

— Recommend early anatomy scan with cord insertion documentation in future pregnancies

— IVF patients should be counseled regarding recurrent risk if future ART planned

— Discuss postpartum contraception before discharge

— Long-acting reversible contraception (LARC) — IUD or implant — can be placed before discharge

— Lactational amenorrhea limited efficacy

— Screen for postpartum depression and PTSD, especially after acute hemorrhagic event or NICU course

— Edinburgh Postnatal Depression Scale at 2 and 6 weeks

— Refer to perinatal mental health services as needed

Postpartum maternal care after vasa previa cesarean:

Neonatal care:

Counseling for future pregnancies:

Contraception:

Mental health:

Step 3 management: At the 6-week postpartum visit, address: (1) cesarean wound healing, (2) contraception, (3) depression screening (EPDS), (4) breastfeeding support, (5) counseling for future pregnancy regarding need for early cord insertion documentation. Document plan for any subsequent pregnancy to flag MFM consultation early

Follow-Up, Monitoring Parameters, and Counseling

— Confirmatory TVUS at 32 weeks

— Weekly nonstress tests starting 28–32 weeks

— Growth ultrasound every 3–4 weeks from 28 weeks (especially with VCI to detect FGR)

— Cervical length surveillance — short cervix may prompt earlier admission

— Daily fetal kick counts at home

— Admit 30–34 weeks: continuous or twice-daily FHR monitoring, betamethasone course, type and screen, MFM rounds

— Earlier if symptomatic (bleeding, contractions, short cervix)

— Pelvic rest — no intercourse, no tampons, no douching, no digital cervical exams

— Recognize warning signs: any vaginal bleeding, rupture of membranes, contractions, decreased fetal movement → present immediately

— Avoid prolonged travel away from hospital

— Plan for early admission if labor symptoms develop

— Confirm gestational age accurately

— Schedule cesarean 34 0/7–37 0/7 weeks based on risk

— Multidisciplinary team meeting before delivery

— 2-week wound check (if cesarean concerns)

— 6-week comprehensive postpartum visit

— NICU follow-up for neonate if applicable

— Early intervention referral for neonates with HIE or developmental concerns

— Vasa previa itself doesn't confer long-term maternal disease risk

— Cesarean history affects future delivery planning (VBAC counseling)

Antenatal follow-up cadence (confirmed vasa previa):

Hospitalization milestones:

Counseling topics:

Delivery planning:

Postpartum follow-up:

Long-term maternal health:

CCS pearl: For an outpatient managed vasa previa pregnancy, your standing weekly orders are: NSTs, fetal kick counts review, cervical length check (every 2 weeks), reinforce precautions, confirm hospital plan. Document patient understanding of warning signs at every visit — this is both clinical and medicolegal best practice

Ethical, Legal, and Patient Safety Considerations

— Discuss risks: maternal surgical risks, neonatal late-preterm morbidity (RDS, TTN, hypoglycemia, NICU admission)

— Discuss benefits: dramatic reduction in fetal mortality (~3% vs 56%)

— Discuss alternatives: expectant management with strict precautions (higher risk if labor begins)

— Document patient understanding, especially regarding refusal of cesarean

— Pregnant patients with capacity have right to refuse any intervention, even when fetal life is at stake

— Ethical principle: maternal autonomy supersedes fetal interests in US law

— Engage ethics consultation, social work, MFM, patient advocate

— Document discussions thoroughly; offer continued surveillance

— Failure to document cord insertion on second-trimester ultrasound is a well-recognized safety gap

— Many institutions now mandate cord insertion documentation as a quality metric

— Standardized ultrasound checklists improve detection

— Patients with vasa previa diagnosed at one center transferring to another for delivery — ensure imaging, MFM consultation notes, and delivery plan transfer

— Verbal handoff at admission; written plan in chart

— High-risk for missed diagnosis if care is fragmented

— Not specific to vasa previa, but intimate partner violence (which may present with abdominal trauma and bleeding) requires screening per ACOG; reporting laws vary by state

— Failure to identify placental anomalies or vasa previa, failure to schedule appropriate cesarean, delayed response to fetal distress — all common litigation triggers

— Defense: meticulous documentation, adherence to SMFM guidelines, multidisciplinary planning

Informed consent for scheduled late-preterm cesarean:

Maternal refusal of cesarean:

Patient safety — diagnostic vigilance:

Transition of care risks:

Mandatory reporting:

Malpractice exposure:

Step 3 management: When counseling for scheduled cesarean for vasa previa, document: risks and benefits explained, alternatives discussed, patient questions answered, signs of warning reviewed, plan for hospitalization and timing of delivery confirmed. If patient declines, involve ethics, document refusal, offer continued surveillance, ensure she understands fetal mortality risk

High-Yield Associations and Rapid-Fire Clinical Facts

Vasa previa incidence: ~1 in 2,500 deliveries

Velamentous cord insertion incidence: ~1% singletons, ~15% monochorionic twins

Mortality undiagnosed: ~56–60%; diagnosed antenatally: <3%

Type I vasa previa: associated with velamentous cord insertion

Type II vasa previa: associated with bilobed or succenturiate-lobed placenta

Risk factors mnemonic — "VIM": Velamentous insertion, IVF, Multiple gestation (plus bilobed placenta and second-trimester low-lying placenta)

Classic triad: ROM → painless vaginal bleeding → fetal bradycardia/sinusoidal tracing

Diagnostic modality: TVUS with color and pulsed Doppler at 28–32 weeks (fetal-rate waveform)

Apt test: distinguishes fetal from maternal blood (fetal Hb resists alkali denaturation, stays pink)

Delivery timing: scheduled cesarean 34 0/7–37 0/7 weeks

Antenatal steroids: betamethasone 28–32 weeks

Hospitalization: 30–34 weeks for confirmed vasa previa

Velamentous insertion alone (without vasa previa): vaginal delivery acceptable; serial growth ultrasounds for FGR

Sinusoidal FHR pattern: wave-like baseline, 3–5 cycles/min, 5–15 bpm amplitude → think fetal anemia (vasa previa or FMH)

Universal anatomy scan documentation: ACOG/SMFM endorse documenting placental cord insertion site as standard of care

Neonatal management: O-negative uncrossmatched blood at bedside, 10–20 mL/kg PRBC if hemorrhagic shock

Recurrence in subsequent pregnancies: low for vasa previa specifically; placental anomalies may recur

TTTS association: monochorionic twins with velamentous insertion at increased risk

Board pearl: If the question stem mentions IVF + accessory placental lobe or IVF + low-lying placenta in second trimester, the test-writer is almost certainly steering toward vasa previa — order TVUS with color Doppler as the next step

Board Question Stem Patterns

— Answer: Emergent cesarean delivery

— Distractors: tocolysis (wrong), TVUS (delays care), digital exam (worsens), maternal transfusion (mother is stable)

— Answer: Transvaginal ultrasound with color Doppler at 28–32 weeks

— Answer: Antenatal corticosteroids 28–32 weeks, hospitalization 30–34 weeks, scheduled cesarean at 34–37 weeks

— Answer: Placental abruption (not vasa previa — pain + maternal instability are key)

— Answer: Fetal blood (vasa previa)

— Answer: Serial growth and Doppler ultrasound, TVUS for vasa previa, monitor for TTTS

— Answer: Engage MFM, ethics, social work; document risks; respect autonomy; offer continued surveillance and counseling

— Answer: Vaginal delivery acceptable with continuous intrapartum monitoring; serial growth scans for FGR

Stem 1 — Acute intrapartum: "A 32-year-old G2P1 at 38 weeks with spontaneous rupture of membranes develops sudden painless bright-red vaginal bleeding. Fetal heart tracing shows sinusoidal pattern. Maternal BP and HR are normal. Next step?"

Stem 2 — Second-trimester imaging: "Anatomy scan at 20 weeks in an IVF pregnancy reveals a velamentous cord insertion and a succenturiate placental lobe. Next step?"

Stem 3 — Confirmed vasa previa management: "TVUS at 32 weeks confirms vasa previa. Patient asymptomatic, single fetus, posterior placenta. Optimal management?"

Stem 4 — Differential: "G3P2 at 36 weeks presents with painful vaginal bleeding, rigid uterus, fetal bradycardia, and maternal hypotension. Likely diagnosis?"

Stem 5 — Apt test scenario: "Vaginal blood after ROM is tested with alkali; sample remains pink. Source?"

Stem 6 — Twin pregnancy: "Monochorionic twins at 22 weeks with velamentous cord insertion in twin A. Best surveillance plan?"

Stem 7 — Patient refusal: "Patient with vasa previa refuses scheduled cesarean. Next step?"

Stem 8 — Velamentous without vasa previa: "Routine scan shows velamentous cord insertion without vessels overlying the cervix. Mode of delivery?"

Key distinction: Watch the pain vs no pain, maternal stable vs unstable, ROM trigger vs spontaneous triad — these three features sort vasa previa from abruption from placenta previa in seconds

One-Line Recap

Vasa previa is the obstetric emergency in which unprotected fetal vessels — most commonly from a velamentous cord insertion or succenturiate placental lobe — overlie the cervix and rupture with the membranes, causing painless vaginal bleeding with fetal bradycardia or a sinusoidal heart tracing in a hemodynamically stable mother, and is survivable only when identified prenatally by transvaginal color Doppler and delivered by scheduled cesarean at 34–37 weeks before labor begins.

Diagnosis: TVUS with pulsed Doppler showing pulsatile vessels at fetal heart rate overlying or within 2 cm of the internal cervical os, screened in high-risk pregnancies (IVF, twins, velamentous insertion, bilobed/succenturiate placenta, second-trimester low-lying placenta)

Management: Scheduled cesarean 34 0/7–37 0/7 weeks, betamethasone 28–32 weeks, hospitalization 30–34 weeks, pelvic rest, no digital cervical exams; emergent cesarean for any bleeding + fetal distress

Differentiate: Painless bleeding + ROM + sinusoidal/bradycardic FHR + stable mother = vasa previa; painful bleeding + rigid uterus + maternal instability = abruption; painless bleeding without trigger + possible maternal instability = placenta previa

Velamentous cord insertion alone (without vasa previa) permits vaginal delivery with continuous monitoring; surveil for FGR

Board pearl: Mortality drops from ~56% (undiagnosed) to <3% (antenatally diagnosed) — this single fact is the rationale for universal anatomy-scan documentation of placental cord insertion site and is the most testable statistic in this topic on Step 3